Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
Phase 2
- Conditions
- MigraineMigraine HeadacheMigraine DisordersMigraine With AuraMigraine Without Aura
- Interventions
- Drug: AST-726 Low doseDrug: AST-726 High doseDrug: AST-726 Placebo
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Ariston Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00285402
- Locations
- 🇫🇮
Suomen Terveystalo Jyvaskyla, Jyvaskyla, Vainonkatu 30, Finland
🇬🇧Stanwell Road Surgery, 25 Stanwell Road, Ashford, Middlesex, United Kingdom
🇫🇮Porin Laakerikeskus, Itsenalsyydenk. 33, Pori, Finland
© Copyright 2025. All Rights Reserved by MedPath